VOYAGER THERAPEUTICS INC (VYGR)
US92915B1061 - Common Stock
Overall VYGR gets a fundamental rating of 5 out of 10. We evaluated VYGR against 565 industry peers in the Biotechnology industry. VYGR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. While showing a medium growth rate, VYGR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VYGR had positive earnings in the past year.
VYGR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: VYGR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of VYGR (6.07%) is better than 95.37% of its industry peers.
With an excellent Return On Equity value of 7.84%, VYGR belongs to the best of the industry, outperforming 95.02% of the companies in the same industry.
VYGR has a Return On Invested Capital of 2.46%. This is amongst the best in the industry. VYGR outperforms 94.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 7.84% | ||
| ROIC | 2.46% |
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 15.80%, VYGR belongs to the best of the industry, outperforming 96.26% of the companies in the same industry.
VYGR's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 7.25%, VYGR belongs to the best of the industry, outperforming 94.84% of the companies in the same industry.
In the last couple of years the Operating Margin of VYGR has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.25% | ||
| PM (TTM) | 15.8% | ||
| GM | N/A |
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VYGR is destroying value.
VYGR has more shares outstanding than it did 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VYGR has an Altman-Z score of 2.42. This is not the best score and indicates that VYGR is in the grey zone with still only limited risk for bankruptcy at the moment.
VYGR has a better Altman-Z score (2.42) than 72.95% of its industry peers.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.42 |
ROIC/WACC0.22
WACC10.99%
2.3 Liquidity
A Current Ratio of 8.45 indicates that VYGR has no problem at all paying its short term obligations.
The Current ratio of VYGR (8.45) is better than 74.56% of its industry peers.
VYGR has a Quick Ratio of 8.45. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a better Quick ratio (8.45) than 74.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.45 | ||
| Quick Ratio | 8.45 |
3. Growth
3.1 Past
The earnings per share for VYGR have decreased strongly by -42.28% in the last year.
VYGR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 48.16% yearly.
VYGR shows a small growth in Revenue. In the last year, the Revenue has grown by 3.33%.
VYGR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 101.11% yearly.
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5YN/A
EPS Q2Q%72.88%
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Sales Q2Q%433.79%
3.2 Future
VYGR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.29% yearly.
The Revenue is expected to decrease by -7.89% on average over the next years.
EPS Next Y-130.32%
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%
EPS Next 5Y-16.29%
Revenue Next Year-45.41%
Revenue Next 2Y-33.96%
Revenue Next 3Y-20.31%
Revenue Next 5Y-7.89%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
VYGR is valuated reasonably with a Price/Earnings ratio of 8.32.
Compared to the rest of the industry, the Price/Earnings ratio of VYGR indicates a rather cheap valuation: VYGR is cheaper than 98.22% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.54. VYGR is valued rather cheaply when compared to this.
VYGR is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -15.5 |
4.3 Compensation for Growth
VYGR has a very decent profitability rating, which may justify a higher PE ratio.
VYGR's earnings are expected to decrease with -33.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%
5. Dividend
5.1 Amount
No dividends for VYGR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VOYAGER THERAPEUTICS INC
NASDAQ:VYGR (12/26/2024, 4:30:01 PM)
After market: 5.91 0 (0%)5.91
+0.13 (+2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners69.44%
Inst Owner Change-4.92%
Ins Owners0.88%
Ins Owner Change0.61%
Market Cap322.86M
Analysts87.5
Price Target18.02 (204.91%)
Short Float %5.64%
Short Ratio4.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.17%
Min EPS beat(2)56.91%
Max EPS beat(2)65.43%
EPS beat(4)4
Avg EPS beat(4)175.61%
Min EPS beat(4)55.44%
Max EPS beat(4)524.68%
EPS beat(8)7
Avg EPS beat(8)122.4%
EPS beat(12)9
Avg EPS beat(12)104.24%
EPS beat(16)12
Avg EPS beat(16)80.58%
Revenue beat(2)2
Avg Revenue beat(2)154.78%
Min Revenue beat(2)103.06%
Max Revenue beat(2)206.51%
Revenue beat(4)4
Avg Revenue beat(4)185.17%
Min Revenue beat(4)103.06%
Max Revenue beat(4)327.88%
Revenue beat(8)7
Avg Revenue beat(8)139.79%
Revenue beat(12)9
Avg Revenue beat(12)112.15%
Revenue beat(16)10
Avg Revenue beat(16)75.54%
PT rev (1m)2.58%
PT rev (3m)0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.5%
EPS NY rev (1m)30.07%
EPS NY rev (3m)34.42%
Revenue NQ rev (1m)-4.9%
Revenue NQ rev (3m)54.33%
Revenue NY rev (1m)26.08%
Revenue NY rev (3m)31.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | N/A | ||
| P/S | 1.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.98 | ||
| P/tB | 0.98 | ||
| EV/EBITDA | -15.5 |
EPS(TTM)0.71
EY12.01%
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS3
BVpS6.05
TBVpS6.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 7.84% | ||
| ROCE | 3.11% | ||
| ROIC | 2.46% | ||
| ROICexc | 25.72% | ||
| ROICexgc | 25.72% | ||
| OM | 7.25% | ||
| PM (TTM) | 15.8% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y62.34%
ROICexcg growth 5YN/A
ROICexc growth 3Y62.34%
ROICexc growth 5YN/A
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 81.45% | ||
| Cap/Sales | 2.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.45 | ||
| Quick Ratio | 8.45 | ||
| Altman-Z | 2.42 |
F-Score3
WACC10.99%
ROIC/WACC0.22
Cap/Depr(3y)48.23%
Cap/Depr(5y)148.03%
Cap/Sales(3y)3.9%
Cap/Sales(5y)5.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5YN/A
EPS Q2Q%72.88%
EPS Next Y-130.32%
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%
EPS Next 5Y-16.29%
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Sales Q2Q%433.79%
Revenue Next Year-45.41%
Revenue Next 2Y-33.96%
Revenue Next 3Y-20.31%
Revenue Next 5Y-7.89%
EBIT growth 1Y-72.64%
EBIT growth 3Y64.52%
EBIT growth 5YN/A
EBIT Next Year-264.72%
EBIT Next 3Y-67.27%
EBIT Next 5Y-41.02%
FCF growth 1Y-418.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-325.34%
OCF growth 3YN/A
OCF growth 5YN/A